Lactoferrin and Helicobacter pylori eradication

Most claims graded on this site rest on laboratory work that human trials later failed to confirm. This one runs the other way. Bovine lactoferrin added to standard antibiotic therapy for Helicobacter pylori has been through repeated randomized testing. Two reviews pooled the trials available by 2009, nine of them in the larger review, and both pooled results favor lactoferrin.

The claim is narrow, and the wording matters. No trial has tested lactoferrin as a treatment for H. pylori on its own. Every trial below added it to antibiotics and measured whether more people cleared the infection.

What the two reviews found

Both reviews appeared in 2009 and reached the same direction from partly overlapping sets of trials.

Zou and colleagues pooled nine randomized trials covering 1,343 patients. By intention-to-treat, 86.57% of those given lactoferrin cleared the infection against 74.44% of those who were not, an odds ratio of 2.26. Side effects also fell, from 16.28% to 9.05%, with nausea showing the largest drop.

Sachdeva and Nagpal screened 169 studies and found five that met their criteria, covering 682 patients. Their pooled odds ratio was 2.22 by fixed effects and 2.24 by random effects, with no significant heterogeneity between trials. The pooled risk difference was 0.11, meaning about one extra person cleared the infection for every nine treated. Their conclusion used the word "potentially" and called the available evidence limited.

That caution was appropriate, and no review has updated it. A PubMed search on 2026-09-23 for systematic reviews or meta-analyses of lactoferrin and H. pylori returns these two papers and nothing else. The pooled evidence on this question is seventeen years old.

The trials since

Three studies have tested the same question since, and none changes the direction.

The largest is Hablass and colleagues in Alexandria, who randomized 400 infected patients to four arms: proton-pump-based triple therapy, sequential therapy, and each of those plus bovine lactoferrin for two weeks. In the per-protocol analysis, adding lactoferrin raised success from 70.3% to 85.6% for triple therapy and from 82.8% to 94.5% for sequential therapy. Adding lactoferrin was an independent predictor of eradication in their model.

The most recent is a 2026 Egyptian trial that used a 2x2 factorial design to ask two questions at once: whether clarithromycin or levofloxacin performed better as the antibiotic backbone, and whether lactoferrin helped either. It found no difference between the antibiotics, both at 72.5%, and a clear difference from lactoferrin, 93.8% against 72.5% by intention-to-treat. The trial was open-label, enrolled 160 people, and its authors wrote that the evidence "proves" lactoferrin should be used as an adjunct. A trial of that size does not prove anything on its own, whatever its result.

The 2019 Italian study is often counted with the trials but was not randomized. It compared 53 patients given levofloxacin triple therapy with lactoferrin against 24 given the regimen alone. The accompanying culture work is the more solid part: lactoferrin and levofloxacin together were synergistic against all seven H. pylori strains tested, cutting the levofloxacin concentration needed by up to sixteen-fold.

The weakness the trials share

Four features recur across this literature, and they are the reason the grade stops short of Established.

Most of these trials were open-label, and several compared lactoferrin against no treatment rather than against a placebo. Eradication is measured by urea breath test or stool antigen, so the outcome itself resists bias, but knowing the assignment can still change how carefully someone takes a two-week antibiotic course.

The geography is narrow. The recent trials come from Egypt and Italy, the older pooled trials largely from Japan and Italy. Antibiotic resistance patterns differ sharply by region. Both 2026 arms without lactoferrin cleared only 72.5% of infections, and a regimen failing more than a quarter of the time leaves an adjunct more room to show a benefit than one that rarely fails.

Analysis method varies. Hablass reported per-protocol results, which flatter any intervention by dropping people who stopped treatment. The 2009 reviews and the 2026 trial used intention-to-treat.

Finally, no trial has tested a dose-response relationship or lactoferrin against a recognized adjunct such as a probiotic. The trials establish that something happens when lactoferrin is added, not how much is needed or how it compares with the alternatives.

Why the grade is Supported

The scale reserves Established for claims replicated in more than one adequately powered human trial. This claim has the replication: two independent reviews, several trials since, all pointing the same way, with an effect size large enough that design flaws alone are an awkward explanation for it. What it lacks is a large blinded trial with a placebo arm in a Western first-line population, run under current resistance conditions and reported by intention-to-treat. Until one exists, Supported is the honest ceiling.

The direction of this finding also fits the mechanism better than most lactoferrin claims do. The infection sits on the gastric mucosa, where swallowed protein arrives at a real concentration, which is exactly the objection that sinks the antibacterial claim in settings further down the gut. The culture work behind this one is specific too: synergy with levofloxacin against resistant strains, and suppression of bacterial motility.

The side effect finding travels with the eradication finding and is covered on the lactoferrin side effects page. The two reviews disagree about it, which is worth reading alongside the eradication numbers rather than after them. Where this claim sits against the rest of the record on lactoferrin is set out in the ledger on the homepage.